
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics Inc. is poised for growth, with expectations of a meaningful strengthening of its oncology portfolio over the next 12-18 months, including several key product launches such as Precise MRD and enhancements to MyRisk. The financial outlook indicates a projected total revenue growth of approximately 6% year-over-year by 2026, driven largely by a 10% growth in prenatal testing and mid-single-digit increases across hereditary cancer testing, tumor profiling, and pharmacogenomics. Despite some near-term challenges, particularly in the integration of electronic medical records for hereditary testing, the anticipated increases in test volumes across various segments support a positive long-term view on Myriad's stock.
Bears say
The excerpts indicate a significant downgrade of Myriad Genetics's stock to Sector Perform, along with a lower price target set at $6. This repeated downgrade suggests a consensus among analysts regarding concerns over the company's financial performance and future growth potential. The lack of upward momentum in the stock's valuation highlights underlying challenges that may affect investor confidence in Myriad Genetics's market position and profitability.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares